Skip to content
Medical Health Aged Care, Regional Country Services

Rural health conference in Traralgon – run by and for medical students and junior doctors

Monash University 2 mins read
Key Facts:
  • A rural health research conference in Traralgon, Victoria, is being organised and run by medical students and junior doctors
  • One-third of Australians live in rural areas but face poorer health outcomes and shorter life expectancy than metropolitan residents
  • The conference highlights research on rural paediatric allergies, aged care access and non-surgical abortion availability in remote areas
  • Despite $20 billion in federal research funding since 2015, only £300 million was allocated to rural health research
  • The DRIVERS conference, initiated in 2021, aims to develop leadership skills among junior doctors and promote peer review research in rural healthcare

Rural health conference in Traralgon – run by and for medical students and junior doctors

One-third of Australians live in rural, regional and remote (RRR) areas. For some of these communities the health outcomes are poor and life expectancy is shorter than those living in metropolitan areas.

This week, Traralgon in Victoria’s Gippsland will be hosting a rural health research conference designed and run by medical students and junior doctors, to promote their leadership and networking abilities.

The conference is also showcasing some amazing research on paediatric allergy presentations to rural health clinics, as well as the difficulties accessing aged care facilities and non-surgical abortions in remote, regional and rural areas.

Funding for research into rural health remains low in comparison to that done in metro areas. For instance, since its inception in 2015 until 30 April 2023, the Federal Government’s Medical Research Future Fund has allocated $20 billion to research funding but invested just under $300 million on research being conducted in regional, rural and remote (RRR) areas and $86.5 million awarded to organisations located in RRR areas.

In 2021 the Doctors for Regional Innovation, Vision, Excellence, Research & Scholarship (DRIVERS) conference was born out of an idea by Monash University’s Associate Professor Janelle Brennan to get junior doctors from Victoria’s Loddon Mallee region to lead an entire scientific conference, from making up the organising and scientific committees, designing the program, suggesting the speakers and hosting sessions, which is an enormous task and a great introduction to leadership and training in the rigors of peer review of research.

Now, for the first time, it is being hosted in Traralgon by the Gippsland Regional Training Hub from 10-11 October 2025.

Associate Professor Rob Dawson, Director of the Gippsland Regional Training Hub, says: "We're not just training future clinicians – we're investing in the future of Gippsland."

While hosted by Monash University’s School of Rural Health, the DRIVERS conference is open to all regional and metropolitan medical students and healthcare workers with research relevant to rural medicine. To learn more, visit monash.edu/drivers

 

 

 

 

 

 

 

 

 

***ENDS***

 

 

 

 

 


Contact details:

For media enquiries please contact:

 

Monash University

Tania Ewing Media and Communications Contractor
E: [email protected]

T: +61 (0) 408 378 422

 

For more Monash media stories, visit our news and events site 


For general media enquiries please contact:
Monash Media
E: [email protected]
T: +61 (0) 3 9903 4840

 

Media

More from this category

  • Medical Health Aged Care
  • 08/12/2025
  • 10:11
BeOne Medicines Ltd.

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLL Sonrotoclax in combination with BRUKINSA demonstrated rapid…

  • Contains:
  • Medical Health Aged Care
  • 08/12/2025
  • 09:40
Miltenyi Biomedicine

Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting

DALY 2-EU results show zamtocabtagene autoleucel (zamto-cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients with relapsed/refractory large B-cell lymphoma (r/r LBCL)1Zamto-cel was well-tolerated in the majority of patients. DALY 2-EU included a high-risk study population, characterized by older age and clinically high-risk disease featuresA 12-day manufacturing time resulted in a vein-to-vein time of 14-16 days, reducing the likelihood for bridging therapy.BERGISCH GLADBACH, Germany, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Miltenyi Biomedicine today announced results from the pivotal DALY 2-EU trial evaluating the efficacy and safety of zamtocabtagene autoleucel (zamto-cel) compared with standard chemoimmunotherapy (R-GemOx or Pola-BR) in patients with…

  • Medical Health Aged Care, Seniors Interest
  • 08/12/2025
  • 08:56
Monash University

Men and women may need different medications to avoid broken bones

A new international study, published in Osteoporosis International and led by Monash’s Centre for Medicine Use and Safety (CMUS), investigated the risks of a…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.